

# Corso FAD ECM

## INNI -

# SCLEROSI MULTIPLA



# Gemelli



**SCLE  
ROSI  
MULT  
iPLA**  
fondazione  
italiana

un mondo  
libero dalla SM

Provider ECM n. 5599

## The Italian Neuroimaging Network Initiative (INNI)



apr. '23

Fondazione Policlinico Universitario Agostino Gemelli IRCCS  
Università Cattolica del Sacro Cuore





This work is licensed under a Creative Commons Attribution 4.0 International License.

*TSRM Ada Guidi - Marino Gentile  
Radiographer*


# Gemelli

✉ [marino.gentile@outlook.com](mailto:marino.gentile@outlook.com)  
✉ [www.variodyne.it](http://www.variodyne.it)

apr. '23

Fondazione Policlinico Universitario Agostino Gemelli IRCCS  
Università Cattolica del Sacro Cuore





THE ITALIAN NEUROIMAGING  
NETWORK INITIATIVE (INNI)

*Verso la standardizzazione dell'utilizzo della  
RM nel paziente con Sclerosi Multipla a  
livello nazionale*

# Gemelli



## The Italian Neuroimaging Network Initiative (INNI): verso la standardizzazione dell'utilizzo della RM nel paziente con Sclerosi Multipla a livello nazionale

apr. '23

SCUOLA ASSOCIATIVA      CORSI ECM  
**AISM    FISM**

Fondazione Policlinico Universitario Agostino Gemelli IRCCS  
Università Cattolica del Sacro Cuore





# THE ITALIAN NEUROIMAGING NETWORK INITIATIVE (INNI)

*Verso la standardizzazione dell'utilizzo della  
RM nel paziente con Sclerosi Multipla a  
livello nazionale*

Gennaio - Novembre 2023



# Programma del Corso

## INTRODUZIONE

*M.A. Battaglia, M. Filippi*

## LINEE GUIDA PER L'ACQUISIZIONE E LA REFERTAZIONE DELLA RM NEL PAZIENTE CON SM

*P. Pantano*

## VERSO LA STANDARDIZZAZIONE DELLA VALUTAZIONE DELLE LESIONI DELLA SOSTANZA BIANCA NEL PAZIENTE CON SM

*M. A. Rocca*

## VERSO UNA STANDARDIZZAZIONE PER LA MISURAZIONE DELL'ATROFIA NEL PAZIENTE CON SM

*N. De Stefano*

## COLLABORAZIONE CON IL REGISTRO SM: CONDIVISIONE DELLA SURVEY CONOSCITIVA

*A. Gallo*

## DISCUSSIONE

*M. Filippi, M. Trojano*



SCUOLA ASSOCIATIVA  
**AISM FISM**

<https://www.aism.it/>

**SCLE  
ROSI  
MULT  
iPLA**  
fondazione  
italiana

un mondo  
**libero** dalla SM

Provider ECM n. 5599

Gemelli



apr. '23



# INNI - database

Il data base INNI - [www.inni-ms.org/](http://www.inni-ms.org/) - raccoglie oggi i dati di risonanza magnetica di un certo numero di Centri Clinici SM che hanno già aderito al progetto. I dati comprendono non solo esami di risonanza magnetica, ma anche le informazioni demografiche, cliniche e neuropsicologiche. Dal 2014 i progetti di ricerca INNI hanno contribuito a sviluppare nuovi protocolli di risonanza magnetica e metodologie appropriate per la gestione dei dati multicentrici nella SM, in particolare per quanto riguarda l'acquisizione ed elaborazione di immagini relative alla valutazione delle lesioni della sostanza bianca e dell'atrofia. Parametri quest'ultimi strumentali alla diagnosi e al monitoraggio della progressione della malattia.



# INNI – Sclerosi Multipla



## DATI EPIDEMIOLOGICI E RICERCHE SPECIFICHE PER VALUTARE L'IMPATTO DELL'INFEZIONE COVID-19 NELLE PERSONE CON SM IN TRATTAMENTO CON TERAPIE MODIFICANTI LA MALATTIA, E ORA CON I VACCINI



### REGISTRO ITALIANO SM



<https://registroitalianosm.it/index.php>



Gemelli



un mondo  
libero dalla SM




apr. '23



# INNI – Sclerosi Multipla


La RM ha completamente rivoluzionato l'approccio al paziente con SM  
in termini di diagnosi, prognosi e monitoraggio del trattamento



# INNI – Sclerosi Multipla

## Diagnostic Criteria

**Dissemination in time.** The development or appearance of new CNS lesions over time.



# INNI – Sclerosi Multipla

[Home](#)   [Project](#)   [News](#)   [Documents](#)   [Login](#)

## Advanced MRI

fMRI

DTI

T1-3D

CENTRO SAN RAFFAELE

EUROPEA UNIUNI

UNIVERSITÀ DI SIENA

V:  
Università degli Studi della Campania  
Luigi De Mattei  
Dipartimento di Medicina e Chirurgia  
Dipartimento di Scienze Motorie e Chirurgico-Dentistiche

SAPIENZA  
Università di Roma

SCLEROSI MULTIPLA  
fondazione  
lavoro & salute  
un mondo  
libero dalla SM

# INNI – Sclerosi Multipla

## Diagnostic Criteria

**Dissemination in space.** At least two MRI lesions in specific CNS locations.

- **Cortical MRI lesions**
- **Juxtacortical MRI lesions**
- **Periventricular MRI lesions**
- **Infratentorial MRI lesions**
- **Spinal cord MRI lesions**




# INNI – Sclerosi Multipla

## Cortical MRI lesions

Lesions seen with special MRI techniques\* within the cerebral cortex (leukocortical, purely intracortical or subpial lesions)


\*DIR, PSIR, T2\*, T1



# INNI – Sclerosi Multipla

## Juxtacortical MRI lesions

T2-w hypointense white matter lesions abutting the cortex, and not separated from it by white matter



**SCLE  
ROSI  
MULT  
IPLA**  
fondazione  
italiana

un mondo  
libero dalla SM





**BEST  
HOSPITALS**  
Newsweek  
L'OSPEDALE IN ITALIA  
statista

# INNI – Sclerosi Multipla

## Periventricular MRI lesions


T2-w hypointense white matter lesions abutting the lateral ventricles without white matter in between, including lesions in the corpus callosum but excluding lesions in deep grey matter structures



# INNI – Sclerosi Multipla

## Infratentorial MRI lesions



T2-w hypointense lesions in the brainstem, cerebellar peduncles, or cerebellum



# INNI – Sclerosi Multipla

## Spinal cord MRI lesions



Hyperintense lesions in the spinal cord seen on T2 plus short tau inversion recovery, proton-density images, or other appropriate sequences, or in two planes on T2 images



Courtesy of Dr. C. Mainero, MGH



# INNI – Sclerosi Multipla



# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

### 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis

Mike P Wattjes, Olga Ciccarelli, Daniel S Reich, Brenda Banwell, Nicola de Stefano, Christian Enzinger, Franz Fazekas, Massimo Filippi, Jette Frederiksen, Claudio Gasperini, Yael Hacohen, Ludwig Kappos, David K B Li, Kshitij Mankad, Xavier Montalban, Scott D Newsome, Jiwon Oh, Jacqueline Palace, Maria A Rocca, Jaume Sastre-Garriga, Mar Tintoré, Anthony Traboulsee, Hugo Vrenken, Tarek Yousry, Frederik Barkhof, Álex Rovira on behalf of the Magnetic Resonance Imaging in Multiple Sclerosis study group, the Consortium of Multiple Sclerosis Centres, and North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group\*

Lancet Neurol 2021; 20: 653-70

Published Online

June 14, 2021

[https://doi.org/10.1016/  
S1474-4422\(21\)00095-8](https://doi.org/10.1016/S1474-4422(21)00095-8)



un mondo  
libero dalla SM



# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

Protocollo standardizzato Encefalo  
Protocollo standardizzato Midollo

- 1 **Basale:  
Diagnosi di SM**
- 2 **Follow-up:  
Monitoraggio**

Attività di malattia

Efficacia del Trattamento

Complicanze del Trattamento



un mondo  
libero dalla SM.



# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

### 1 Basale: Diagnosi di SM

#### BRAIN

Field strength  $\geq 1.5$  T (preferably 3 T)

Slice thickness For 3D imaging, 1 mm isotropic is preferred but, if over contiguous (through plane and in plane), not  $>1.5$  mm, with 0.75 mm overlap; for 2D imaging,  $\leq 3$  mm with no gap (except for diffusion-weighted imaging, for which the slice thickness should be  $\leq 5$  mm with a 10–30% gap)

In-plane resolution  $\leq 1$  mm  $\times$  1 mm

Coverage Whole brain (include as much of cervical cord as possible)

Axial scan orientation Subcallosal plane to prescribe (ie, for 2D imaging) or reformat (ie, for 3D imaging) axial oblique slices

3D=three dimensional. 2D=two dimensional.



# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

### SPINAL CORD

Field strength	$\geq 1.5$ T (3 T has no added value compared with 1.5 T)
Slice thickness	Sagittal slices should be $\leq 3$ mm with no gap; axial slices should be $\leq 5$ mm with no gap
In-plane resolution	$\leq 1$ mm $\times$ 1 mm
Coverage	Cervical and thoracolumbar spinal cord, to include conus
Axial scan orientation	Perpendicular to the sagittal axis of the spinal cord




# INNI – Sclerosi Multipla


## Linee guida per l'uso della RM

### Diagnosi di SM

Three-Tesla MRI does not improve the diagnosis of multiple sclerosis. A multicenter study



66 patients with CIS within 6 months from symptom onset  
collected in 6 MRI European centers



MAGNIMS, Neurology 2018




**SCLE  
ROSI  
MULT  
IPLA**  
fondazione italiana

IST  
ITALIA  
Newsweek  
LE ITALIA  
statista  
un mondo  
libero dalla SMI  
UNIVERSITARIO A. GEMELLI

# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

### Diagnosi di SM



#### Brain MRI protocol

Axial T2-weighted (TSE or FSE) sequences† Recommended

Sagittal T2-weighted FLAIR (preferably 3D; fat suppression is optional) Recommended

Axial T2-weighted FLAIR (unnecessary if a sagittal 3D FLAIR with multiplanar reconstruction is obtained; fat suppression is optional) Recommended

Axial (or 3D sagittal) T1-weighted sequences after contrast‡ Recommended

Diffusion-weighted imaging Optional

Double inversion recovery or PSIR for detecting cortical or juxtacortical lesions Optional

High-resolution T1-weighted sequences (isotropic 3D acquisition; for quantitative assessment of brain volume) Optional

Susceptibility-weighted imaging Optional for assessing the central vein sign




# INNI – Sclerosi Multipla




## Linee guida per l'uso della RM

### Diagnosi di SM


Sequenze raccomandate




3D FLAIR



Assiale T2 TSE



Assiale T1 post mdc



# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

### Diagnosi di SM

#### Sequenze facoltative

Diffusion-weighted imaging

Optional

PML

Double inversion recovery or PSIR for detecting cortical or juxtacortical lesions

Optional

Lesioni corticali

High-resolution T1-weighted sequences (isotropic 3D acquisition; for quantitative assessment of brain volume)




Optional

Volumetria

Susceptibility-weighted imaging

Optional

Vena centrale, iron ring



# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

### Diagnosi di SM

#### RM ENCEFALO

##### In sintesi:

- Campo magnetico  $\geq 1.5\text{ T}$  (preferibile 3T)
- Sezione  $\leq 3\text{ mm}$  (3D imaging preferibile)
- Protocollo di acquisizione e posizionamento della testa standardizzati
- Dose singola di gadolinio ( $0.1 \text{ mmol/kg pc}$ ) con ritardo di 5 min tra iniezione e acquisizione



# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

### Diagnosi di SM

#### Spinal cord MRI protocol

At least two of: sagittal T2-weighted sequences (TSE or FSE), proton density-weighted sequences (TSE or FSE), or STIR

Recommended 

Sagittal 3D heavily T1-weighted sequences (PSIR or magnetisation-prepared rapid acquisition of gradient echoes§) only for the cervical segment

Optional

Axial T2-weighted (TSE or FSE) or gradient-recalled echo to corroborate, characterise, and confirm lesions detected on sagittal images or to detect lesions in spinal cord segments with high clinical suspicions of involvement

Optional

Sagittal T1-weighted sequences (TSE or FSE) before contrast

Optional

Sagittal T1-weighted sequences (TSE or FSE) after contrast‡

Recommended 

Axial T1-weighted sequences (TSE or FSE) after contrast‡

Optional




# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

### Diagnosi di SM

#### SPINAL CORD

T2 TSE




T2 STIR



T1 gd



T2 TSE



# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

### Diagnosi di SM

#### SPINAL CORD


T2 TSE




T2 STIR



1



2



# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

### Diagnosi di SM

#### RM MIDOLLO SPINALE

##### In sintesi:

- Campo magnetico  $\geq 1.5\text{T}$
- Sezione  $\leq 3\text{mm}$  sul piano sagittale
- Protocollo di acquisizione standardizzato con almeno due sequenze T2 sul piano sagittale
- Direttamente dopo somm.ne di dose singola di gadolinio



# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

Protocollo standardizzato Encefalo  
Protocollo standardizzato Midollo

- 1 Basale:  
Diagnosi di SM
- 2 Follow-up:  
Monitoraggio

Attività di malattia

Efficacia del Trattamento

Complicanze del Trattamento

In generale:

- Stesso posizionamento
- Stesso protocollo (semplificato)
- Midollo non sempre necessario
- MDC non sempre necessario





# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

### Follow-up: Monitoraggio

Posizionamento  
Ricostruzione immagini 3D

Linea bicallosale



Diversa ricostruzione dello stesso esame






# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

### Follow-up: Monitoraggio

Riposizionamento non corretto


Esame precedente




# Linee guida per l'uso della RM

## Follow-up: Monitoraggio

Riposizionamento corretto



Esame precedente



CORSI OPERATORI

**SCLE  
ROSI  
MULT  
IPLA**  
fondazione  
italiana

un mondo  
libero dalla SM

# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

### Follow-up: Monitoraggio

### Efficacia del Trattamento



- Protocollo MRI abbreviato (3D-FLAIR + T1 (non sempre necessario post-MDC)
- Se attività MRI (non clinica) follow-up ogni 6 mesi
- Midollo non sempre necessario



# INNI – Sclerosi Multipla

## Linee guida per l'uso della RM

**Follow-up:  
Monitoraggio**

**Complicanze del Trattamento**

### Progressive multifocal leukoencephalopathy (PML)

#### T2w e FLAIR

Area iperintensa, con coinvolgimento fibre a U, bordi sfumati verso la corteccia, circondata da lesioni puntiformi (milk way)

Senza edema o effetto massa

#### T1w



iso- o ipointensa

#### T1 (Gd)

Generalmente NO CE (DD con IRIS)

#### ADC/DWI

Restrizione ai bordi della lesione



# INNI – Sclerosi Multipla

## Il referto radiologico

### TECNICA:

Magnete (1.5 vs 3T), elenco sequenze, mdc (tipo e dose).

### INDICAZIONI CLINICHE:

Sintomatologia (recidiva?), fenotipo, disabilità, trattamento.

Quesito specifico?

### REPERTI:

- Lesioni (T2 e T1gd): numero, dimensioni, forma, sede.
- Valutazione qualitativa o semiquantitativa dell'atrofia cerebrale e/o midollare.
- Follow-up: nuove lesioni T2 e T1gd: numero, dimensioni, forma, sede.
- Altri reperti.

### CONCLUSIONI:

Diagnosi: criteri diagnostici DIS e DIT; attività di malattia; interpretazione radiologica in rapporto al questo clinico; eventuale diagnosi differenziale.

Follow-up: attività di malattia; stabilità o progressione; possibili complicanze (es. PML).





## Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM

M.A. Rocca

Neurology Unit and Neuroimaging of CNS White Matter Unit,  
Division of Neuroscience, San Raffaele Scientific Institute,  
Vita-Salute San Raffaele University, Milan, Italy



un mondo  
libero dalla SM



# INNI – Sclerosi Multipla

## Outline

- The INNI initiative / MRI protocol
- The INNI initiative / Lesion assessment
- The INNI initiative / Quality control
- New automatic approaches for lesion identification and quantification
- Conclusions



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



# INNI – Sclerosi Multipla

## The INNI initiative

- Conventional MR sequences (dual-echo, FLAIR and T1- weighted imaging) provide important pieces of information for diagnosing MS, understanding its natural history and assessing treatment efficacy
- Standardization of MR protocols/procedures outside the setting of clinical trials is still lacking
- The first two goals of the Italian Neuroimaging Network Initiative (INNI) were:
  1. **The creation of a web-based system** with clinical, neuropsychological and MRI data from the participating centers, to allow data sharing
  2. **The use of such data to perform large-scale studies** to define the role of clinical, neuropsychological and advanced MRI biomarkers in understanding MS pathophysiology

**The INNI initiative will help to define standardized MRI and clinical protocols for the evaluation of patients with MS at a national level**



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



Gemelli



un mondo  
libero dalla SM



apr. '23

# INNI – Sclerosi Multipla

## The INNI initiative

Neurol Sci (2017) 38:1029–1038  
DOI 10.1007/s10072-017-2903-z



ORIGINAL ARTICLE

### The Italian Neuroimaging Network Initiative (INNI): enabling the use of advanced MRI techniques in patients with MS

M. Filippi<sup>1,2</sup> · G. Tedeschi<sup>3,4</sup> · P. Pantano<sup>5,6</sup> · N. De Stefano<sup>7</sup> · P. Zaratin<sup>8</sup> ·  
M. A. Rocca<sup>1,2</sup> · For the INNI Network

Available at: [https://data  
base.inni-ms.org](https://data.base.inni-ms.org)

Welcome to INNI-MS  
The Italian Neuroimaging Network Initiative (INNI) to optimize the use of advanced MRI techniques in patients with MS.

**4561 MRI exams uploaded**


Sites	Patients	Data
Current number of sites: 6	Current number of patients: 1773	Current number of MRI exams: 3121

© Corronet-SaFR, 2016

Financially supported by a research Grant from Fondazione Italiana Sclerosi Multipla (FISM 2013/S/1)



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



# INNI – Sclerosi Multipla

## The INNI initiative User interfaces

**MRI exam**

<a href="#">Edit</a>	<a href="#">Delete</a>
Exam date	10/10/2012
Patient age at exam	34
Hash	28ef8246-88343f9b-497a5ef7-1af56a26-a2d91ea4
Study description	FMRI
Scanner	PHILIPS-A04051C Philips Medical Systems

**Study series**

Upload DICOM files			
Serie type	Serie description	Note	Serie ID
3D T1	T1W/3D/VOL/T		2345e57c-dabe112a-881
DTI	dti35-reg		a5e2a3bb-b794bfde-758
DIR	eIDIR		44467b3a-2120dead-da*
Resting State	RESTING		9a0b0d15-43f03cda-3aa
Dual Echo	DUAL_TSE_newFORTE		f7b233bb-a0657018-cf2(

[Edit series from DICOM server](#)

© Consortium GARR 2015

DC-DICOM series

Series Description	3D MRIT T1 axi
Modality	MR
Protocol Name	3D MRIT T1 axi CLEAR
Image ID (acquisition)	150
Series Number	1000

Sequence type

3D T1

Note

6b3be7660b34849

DC-DICOM series

Series Description	RESTING
Modality	MR
Protocol Name	RESTING_3DGE
Image ID (acquisition)	400
Series Number	1000

Sequence type

Resting State

3D T1

DTI

Dwi

Dwi Eels

T2

FLASH

GR

Prot\_Consortium T1

Resting State

Other

Series Description	3DCT_SQW_HASTE
Modality	CT
Protocol Name	3DCT_SQW_HASTE CLEAR
Image ID (acquisition)	400
Series Number	1000

Sequence type

Dwi Eels

Note

ages Series number Actions

801	<a href="#">Delete</a>
701	<a href="#">Delete</a>
601	<a href="#">Delete</a>
501	<a href="#">Delete</a>
401	<a href="#">Delete</a>
301	<a href="#">Delete</a>
201	<a href="#">Delete</a>

Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



Gemelli



**SCLE  
ROSI  
MULTI  
PLA**  
Istruzione Italiana

un mondo  
libero dalla SM

2022  
IST  
ITALIA  
Le ITALIA  
Newsweek  
statista

POLICLINICO UNIVERSITARIO A. GEMELLI

apr. '23

# INNI – Sclerosi Multipla

## The INNI initiative / MRI protocol

**Minimum requirement** of the MRI protocol to be uploaded on INNI:

1. Sequences for lesion quantification: **dual echo (DE)** or **T2-weighted/FLAIR** scans acquired with axial orientation and a slice thickness of no more than 3 mm
2. Sequences for atrophy quantification: high-resolution **3D T1-weighted** scans
3. **DT MRI** sequences acquired with \*30 diffusion-weighted direction and a nearly isotropic spatial resolution
4. **RS fMRI** sequences covering all brain, with at least 140 scans and an acquisition session at least 5 min long

All sequences **should** be acquired on a **3T MR** scanner

Filippi et al., Neurol Sci 2017



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM







# INNI – Sclerosi Multipla

## The INNI initiative / MRI protocol

**MRI parameters** of the sequences used **for lesion assessment** included at the time of the creation of the INNI database by each promoting center

Filippi et al., Neurol Sci 2017

Sequence	Milan	Naples	Rome	Siena
Coil	8 channel head coil	8 channel head coil	12 channel head coil	32 channel head coil
Dual echo	TR = range 2599–2910 ms	TR = 3080 ms	TR = range 3320–5310 ms	TR = 4000 ms
	TE = 16/80 ms	TE = 24/127.5 ms	TE = 10/103 ms	TE = 15/100 ms
	FA = 90°	FA = 90°	FA = 150°	FA = 90°
	Matrix = 256 × 256	Matrix = 256 × 384	Matrix = 384 × 384	Matrix = 240 × 240 (recon 352 × 352)
	FOV = 240 × 240 mm	FOV = 240 × 240 mm	FOV = 220 × 220 mm	FOV = 240 × 240 mm
	Thickness = 3 mm	Thickness = 3 mm	Thickness = range 3 mm	Thickness = 3 mm
	No. of slices = range 44–50	No. of slices = 44	No. of slices = range 45	No. of slices = 44
	Orientation = axial	Orientation = axial	Orientation = axial	Orientation = axial



Prospectively evolving...

Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



un mondo  
libero dalla SM



Gemelli




apr. '23



2022

Newsweek

## The INNI initiative / Collecting data



- No identifying patients' information is stored in the INNI platform
- Patient data are assigned to a unique identification code (ID), one-way function
- To ensure subjects' privacy, any personal information is deleted from DICOM files
- The database content is available for authorized users only



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



un mondo  
libero dalla SM



# INNI – Sclerosi Multipla

## Outline

- The INNI initiative / MRI protocol
- The INNI initiative / Lesion assessment
- The INNI initiative / Quality control
- New automatic approaches for lesion identification and quantification
- Conclusions



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



# INNI – Sclerosi Multipla

## The INNI initiative / Lesion assessment

Practical standardize guidelines for brain T2-hyperintense lesion identification applied to INNI data

**BRAIN**  
A JOURNAL OF NEUROLOGY

**REVIEW**

**Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines**

Massimo Filippi,<sup>1,2,3</sup> Paolo Preziosa,<sup>1,2</sup> Brenda L. Banwell,<sup>4</sup> Frederik Barkhof,<sup>5,6</sup> Olga Ciccarelli,<sup>3,8</sup> Nicola De Stefano,<sup>7</sup> Jeroen J.G. Geurts,<sup>10</sup> Friedemann Paul,<sup>11</sup> Daniel S. Reich,<sup>12</sup> Ahmed T. Toosy,<sup>7</sup> Anthony Traboulsee,<sup>13,14</sup> Mike P. Wattjes,<sup>15</sup> Tarek A. Yousry,<sup>16,17</sup> Achim Gass,<sup>18</sup> Catherine Lubetzki,<sup>19</sup> Brian G. Weinshenker<sup>20</sup> and Maria A. Rocca<sup>1,2</sup>

MRI has improved the diagnostic work-up of multiple sclerosis, but inappropriate image interpretation and application of MRI diagnostic criteria contribute to misdiagnosis. Some diseases, now recognised as conditions distinct from multiple sclerosis, may satisfy the MRI criteria for multiple sclerosis (e.g. neuromyelitis optica spectrum disorders, Sjögren syndrome), thus making the diagnosis of multiple sclerosis more challenging, especially if biomarker testing (such as serum anti-AQP4 antibodies) is not informative. Improvements in MRI technology contribute and promise to better define the typical features of multiple sclerosis lesions (e.g. juxtacortical and periventricular location, cortical involvement). Greater understanding of some key aspects of multiple sclerosis pathobiology has allowed the identification of characteristics more specific to multiple sclerosis (e.g. central vein sign, subpial demyelination and lesional rims), which are not included in the current multiple sclerosis diagnostic criteria. In this review, we provide the clinicians and researchers with a practical guide to enhance the proper recognition of multiple sclerotic lesions, including a thorough definition and illustration of typical MRI features, as well as a discussion of red flags suggestive of alternative diagnoses. We also discuss the possible place of emerging qualitative features of lesions which may become important in the near future.

Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



# INNI – Sclerosi Multipla

## T2-hyperintense lesions

- Focal hyperintensity on a T2-w (T2, T2-FLAIR or similar) or a proton density (PD)-w sequence
- **Round to ovoid** in shape, ranging from a few millimeters to more than one or two centimeters in diameter. Generally,  $\geq 3$  mm in their long axis
- Lesions should be visible on at least **2 subsequent slices** to exclude artifacts or small hyperintensities, although in acquisitions with higher slice thickness (e.g.,  $\geq 3$  millimetres), smaller lesions could be visible on a single slice
- Asymmetrically distributed mainly in the early stages
- Lesions can occur in any CNS region, with a predilection of specific WM regions (periventricular and juxtacortical WM, corpus callosum, infratentorial areas and spinal cord)

Filippi et al., Brain 2019



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



un mondo  
libero dalla SM




apr. '23

49

# INNI – Sclerosi Multipla

## The INNI initiative / Lesion assessment

Filippi et al., Brain 2019



Lesion category	Green flags
<b>Periventricular</b>	Location: abutting the lateral ventricles without intervening white matter
<b>Juxtacortical/ Cortical</b>	Location: touching or within the cortex
<b>Infratentorial</b>	Location: brainstem, cerebellar peduncles and cerebellar hemispheres; contiguous to cisterns or the floor of the fourth ventricle; surface of the pons and the pontine trigeminal root entry zone; lining of CSF border zones; cerebral peduncles and close to the periaqueductal gray matter; uni- or bilateral paramedian location in medulla oblongata



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



# INNI – Sclerosi Multipla

## The INNI initiative / Lesion assessment

Filippi et al., Brain 2019




Lesion category	Green flags
Spinal cord	<p>Multiple discrete (<b>focal</b>) lesions</p> <ul style="list-style-type: none"> <li>- Shape: sagittal: cigar-like; axial: wedge-shaped</li> <li>- Size: small; ≤ 2 vertebral segments; &lt; half of the cord</li> <li>- Location: cervical&gt;thoracic; peripheral region; lateral and posterior columns, but central gray matter not spared</li> <li>- Signal characteristics: T1-hypointensity (&gt; at higher field strengths)</li> </ul>
Gadolinium-enhancing lesions	<ul style="list-style-type: none"> <li>- Shape: nodular; open-ring; closed-ring</li> <li>- Location: brain&gt;spinal cord</li> </ul>

Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM




# INNI – Sclerosi Multipla

## The INNI initiative / Lesion assessment



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



un mondo  
libero dalla SM



# INNI – Sclerosi Multipla

## Outline

- The INNI initiative / MRI protocol
- The INNI initiative / Lesion assessment
- The INNI initiative / Quality control
- New automatic approaches for lesion identification and quantification
- Conclusions



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



un mondo  
libero dalla SM



# INNI – Sclerosi Multipla

## The INNI initiative / Quality control

The collection of multicenter MRI data raises the important issues of **standardization** and **quality control**

Journal of Neurology (2019) 266:2848–2858

<https://doi.org/10.1007/s00415-019-09509-4>

ORIGINAL COMMUNICATION



### MRI quality control for the Italian Neuroimaging Network Initiative: moving towards big data in multiple sclerosis

Loredana Storelli<sup>1,2</sup> · Maria A. Rocca<sup>1,3</sup> · Patrizia Pantano<sup>4,5</sup> · Elisabetta Pagani<sup>1</sup> · Nicola De Stefano<sup>6</sup> · Gioacchino Tedeschi<sup>7</sup> · Paola Zaratin<sup>8</sup> · Massimo Filippi<sup>1,2,3</sup> · For the INNI Network



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM




# INNI – Sclerosi Multipla

## The INNI initiative / Quality control


A quality control (QC) procedure is implemented to characterize and monitor the INNI database, including:

(1) Subject positioning into the MR scanner



$$ED = \sqrt{(x_l - x_c)^2 + (y_l - y_c)^2 + (z_l - z_c)^2},$$

(2) Intensity inhomogeneity




Storelli et al., J Neurol 2019




# INNI – Sclerosi Multipla

## The INNI initiative / Quality control

(3) Image tissue contrast



(4) Presence of image artifacts



Storelli et al., J Neurol 2019

Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM




un mondo  
libero dalla SM



# INNI – Sclerosi Multipla

## The INNI initiative / Quality control

### (4) Quality check and standardization of lesion assessment



1. The **best contrast** between WM, GM, and lesions is set
2. Region of interests (ROIs) should be defined using a **conservative approach** (mildly hyperintense areas around visible lesions should not be included)
3. Check on **longitudinal consistency** of lesion maps




Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM

**SCLE  
ROSI  
MULTI  
PLA**  
fondazione  
italiana  
un mondo  
libero dalla SM

# INNI – Sclerosi Multipla

## The INNI initiative / Quality control



- To reduce variability, the procedure of **QC and pre-processing is centralized**
- QC measures would be available together with MRI data to promote the use of a quality-assessed and standardized database



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



un mondo  
libero dalla SM



BEST  
HOSPITALS  
2022  
Newsweek  
statista

# INNI – Sclerosi Multipla

## The INNI initiative / Quality control

Patient

Hash	305495c91948a2c0def7547f503d12998
Site	San Raffaele Scientific Institute, Vita-Salute San Raffaele University
Country	ITALY (IT)
Race	Caucasian
Fiscal code	800aa203d14aaacf0fa05-8a587867ef17
Marital state	
Employment	
Handedness	R
EHI	100

Added fields and sections

Neurological visit

Patient page	Edit	Delete	Not verified
Actions : Site Data Manager			
New patient	Search patient	Import visits from CSV	Update subjects from CSV

Datasets verification by the Data Controller

Clinical

Type of onset	Monofocal
Symptoms	ON
Disease onset date (dd/mm/yyyy)	01/01/2002
Date of conversion to CDMS (dd/mm/yyyy)	
Date of evolution to SPMS (dd/mm/yyyy)	
Date of evolution to BMS (dd/mm/yyyy)	
Date of reaching EDSS=4 (dd/mm/yyyy)	
Date of reaching EDSS=6 (dd/mm/yyyy)	

Automatization of data upload

Study series

Viewer	Tags	Series type	Series description	Note	Quality	Primary artifact	Secondary artifact	Series ID	Number of Images	Series number	Delete	Preprocessing files upload	Preprocessing files download
								c09e436-a073556-80710384-24362d3e-03c943d1	9001	301			

MRI exam interface

Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



# INNI – Sclerosi Multipla

## Outline

- The INNI initiative / MRI protocol
- The INNI initiative / Lesion assessment
- The INNI initiative / Quality control
- New automatic approaches for lesion identification and quantification
- Conclusions




Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



# INNI – Sclerosi Multipla

## T2-lesion identification in MS: standard approach

- Time-consuming
  - 3D > 2D sequences
  - High > low lesion load
- High intra- and inter-rater variability





Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



# INNI – Sclerosi Multipla

## T2-lesion identification in MS: new approaches

### Lesions segmentation Deep learning



Method	DSC	Sensitivity	Precision	Score
Andermatt et al. (2017)	0.63 (0.14)	0.54 (0.19)	0.84 (0.10)	92.07
Habibi et al. (2018)	0.66 (0.11)	0.67 (0.20)	0.71 (0.16)	91.52
Valverde et al. (2017)	0.64 (0.12)	0.57 (0.17)	0.79 (0.15)	91.44
Birnbaum and Greenbaum (2017)	0.63 (0.14)	0.55 (0.18)	0.80 (0.15)	91.26
Roy et al. (2018) <sup>b</sup>	0.52 (– –)	– (– –)	0.86 (– –)	90.48
Dashgade et al. (2015)	0.60 (0.13)	0.55 (0.17)	0.73 (0.18)	89.81
Jain et al. (2015)	0.55 (0.14)	0.47 (0.15)	0.73 (0.20)	88.74
Shiroi et al. (2010)	0.55 (0.19)	0.54 (0.15)	0.70 (0.29)	88.46
Valcarcel et al. (2018)	0.57 (0.13)	0.57 (0.18)	0.61 (0.16)	87.71
Dude et al. (2015)	0.52 (0.14)	0.46 (0.15)	0.66 (0.18)	86.44
Full train	0.63 (0.13)	0.55 (0.16)	0.79 (0.14)	91.33
One-shot (3 layers, 26.8 ml.3)	0.58 (0.16)	0.48 (0.19)	0.84 (0.13)	90.32

Method	DSC	PPV	LTPR	LFPN	VD	SD	HD
TOADS (Shiroi et al., 2010)	0.5248	0.5965	0.4608	0.6277	0.4659	5.4392	13.60
LBT (Schmid et al., 2012)	0.3622	0.5193	0.1460	0.3844	0.6966	7.0919	14.35
OASIS (Cioweeney et al., 2013)	0.4193	0.3483	0.3755	0.4143	2.0588	3.5688	18.33
U-NET (Chenlongguo et al., 2015a)	0.6376	0.7268	0.3993	0.7267	0.5886	3.9271	9.23
OURS	0.6655	0.8693	0.4465	0.6843	0.3372	2.5751	4.73

Valverde et al., Neuroimage 2018



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



un mondo  
libero dalla SM



# INNI – Sclerosi Multipla

## Automatic assessment of lesion dissemination in space and time



**icobrain ms**

**NeuroQuant® MS**  
FLAIR Lesion and Atrophy Report Plus

**Patient Information:**  
Patient Name: Carlo S.  
Patient ID: 100001  
Sex: M  
Age: 50  
Referring Physician: Dr. Riccardo Pizzetti

**Report Information:**  
Report Date: 2018-01-10  
Scan Acquisition: FLAIR (1.5T)  
Print Date: 2018-01-10  
Software Version: 4.1.0

**Site Information:**  
Dr. Riccardo Pizzetti, MD  
Address: Via 1  
Address Line 2  
Preferred Site Info

**Lesion Dynamics Visualisation:**  
Periventricular, Subcortical, Deep White, Infratentorial

**Lesion Summary:**

Lesion Class	Total	Subcortical	Periventricular	Infratentorial	Deep White
Lesion Burden (ml)	35.61	1.28	28.01	0.00	5.12
Lesion Burden % of White Matter	1.01	0.01	1.01	0.00	0.01
T2 Hyperintense (ml)	35.61	1.28	28.01	0.00	5.12

**Lesion Dynamics:**

Counts (Number)	Total	Subcortical	Periventricular	Infratentorial	Deep White
New	0	0	0	0	0
Increasing	0	0	0	0	0
Decreasing	0	0	0	0	0
Stable	40 (100%)	1 (2.5%)	39 (97.5%)	0	1 (2.5%)
T2 Hyperintense	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

**Brain Structure Volumes:**

Brain Structure	Current Volume	Prior Volume	Volume Change (ml)	N-ICV (Change)	Normalised Percentile (Change)
Absolute Brain	600.07	670.07	-70.00	-11.84%	51.00%
Cerebral Gray Matter	380.28	379.33	+1.00	+0.26%	50.94%
Cerebral White Matter	521.48	522.08	-0.60	-0.11%	50.45%
Pons	6.67	6.65	+0.02	+0.30%	51.00%
Internal Lateral Ventricle	1.03	1.03	-0.00	-0.00%	50.50%
Right Lateral Ventricle	0.57	0.58	-0.01	-1.75%	50.00%
Left Ventricle	0.57	0.57	-0.00	-0.00%	50.00%
Hippocampus	0.67	0.66	+0.01	+1.52%	50.00%

Automatic brain segmentation for lesions. Please carefully review segmentation output for accuracy.

Copyright © 2018 icometrix NV, National Reference Center for MS, 3012 Leuven, Belgium.



**NeuroQuant® MS**  
FLAIR Lesion and Atrophy Report Plus

**Patient Information:**  
Patient Name: Carlo S.  
Patient ID: 100001  
Sex: M  
Age: 50  
Referring Physician: Dr. Riccardo Pizzetti

**Report Information:**  
Report Date: 2018-01-10  
Scan Acquisition: FLAIR (1.5T)  
Print Date: 2018-01-10  
Software Version: 4.1.0

**Site Information:**  
Dr. Riccardo Pizzetti, MD  
Address: Via 1  
Address Line 2  
Preferred Site Info

**Lesion Dynamics Visualisation:**  
Periventricular, Subcortical, Deep White, Infratentorial

**Lesion Summary:**

Lesion Class	Total	Subcortical	Periventricular	Infratentorial	Deep White
Lesion Burden (ml)	35.61	1.28	28.01	0.00	5.12
Lesion Burden % of White Matter	1.01	0.01	1.01	0.00	0.01
T2 Hyperintense (ml)	35.61	1.28	28.01	0.00	5.12

**Lesion Dynamics:**

Counts (Number)	Total	Subcortical	Periventricular	Infratentorial	Deep White
New	0	0	0	0	0
Increasing	0	0	0	0	0
Decreasing	0	0	0	0	0
Stable	40 (100%)	1 (2.5%)	39 (97.5%)	0 (0%)	1 (2.5%)
T2 Hyperintense	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

**Brain Structure Volumes:**

Brain Structure	Current Volume	Prior Volume	Volume Change (ml)	N-ICV (Change)	Normalised Percentile (Change)
Absolute Brain	600.07	670.07	-70.00	-11.84%	51.00%
Cerebral Gray Matter	380.28	379.33	+1.00	+0.26%	50.94%
Cerebral White Matter	521.48	522.08	-0.60	-0.11%	50.45%
Pons	6.67	6.65	+0.02	+0.30%	51.00%
Internal Lateral Ventricle	1.03	1.03	-0.00	-0.00%	50.50%
Right Lateral Ventricle	0.57	0.58	-0.01	-1.75%	50.00%
Left Ventricle	0.57	0.57	-0.00	-0.00%	50.00%
Hippocampus	0.67	0.66	+0.01	+1.52%	50.00%

Automatic brain segmentation for lesions. Please carefully review segmentation output for accuracy.

Copyright © 2018 icometrix NV, National Reference Center for MS, 3012 Leuven, Belgium.

- **Automatic reports** to visualize and obtain volumetric quantification and segmentation of brain structures and lesions
- **T2-hyperintense lesion distribution** according to the McDonald criteria
- Directly **installed on PACS**



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



# INNI – Sclerosi Multipla

## Conclusions

- The creation of a standardized protocol of MRI acquisition to be applied for the study of patients with MS will provide an important step towards a better harmonization of MRI application in the MS field at a national level
- The proposed guidelines for lesion assessment are essential to apply more standardized lesion assessment criteria in MS
- Image QC is another important aspect to ensure a good quality repository for future quantitative analyses using INNI dataset
- The INNI initiative paved the way for a future standardization of MRI analysis in patients with MS
- The use of automatic approaches is appealing, but needs further validations and confirmation on larger multicenter datasets



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM

INSTITUTE OF MEDICAL SCIENCES AND HUMANITIES

Gemelli



**SCLE  
ROSI  
MULTIPLA**  
Istituzione Italiana

un mondo  
libero dalla SM



apr. '23

**BEST  
HOSPITALS**  
2022  
Newsweek  
statista

L'OSPEDALE IN ITALIA  
POLICLINICO UNIVERSITARIO A. GEMELLI

## Ongoing effort and future steps

- Developments of methods for longitudinal assessment of T2 lesion volume and new/enlarged T2 lesions
- Inclusion of T1-hypointense lesions
- Inclusion of cortical lesions
- Verification of availability of other sequences for testing other possible MRI biomarkers (e.g., SWI, quantitative sequences)



Verso una standardizzazione per l'identificazione e misurazione delle lesioni della sostanza bianca nel paziente con SM



# Towards the Standardization of Brain Atrophy in MS

*Nicola De Stefano*

Department of Medicine, Surgery and Neuroscience

University of Siena, Italy




un mondo  
libero dalla SM



# INNI – Sclerosi Multipla

## MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice

Jaume Sastre-Carriga<sup>1,12</sup>, Deborah Pareto<sup>2</sup>, Marco Battaglini<sup>3</sup>, Maria A. Rocca<sup>3,4</sup>,  
Olga Ciccarelli<sup>5,6</sup>, Christian Entinger<sup>7</sup>, Jens Wuerfel<sup>8</sup>, Maria P. Sormani<sup>9,10</sup>,  
Frederik Barkhof<sup>11,12</sup>, Tarek A. Yousry<sup>11,12</sup>, Nicola De Stefano<sup>1</sup>, Mar Tintore<sup>12</sup>,  
Massimo Filippi<sup>1,12</sup>, Claudio Gasperini<sup>11</sup>, Ludwig Kappos<sup>11</sup>, Jordi Rio<sup>1</sup>,  
Jette Frederiksen<sup>13</sup>, Jackie Palace<sup>14</sup>, Hugo Vrenken<sup>11</sup>, Xavier Montalban<sup>1,10</sup>,  
Àlex Rovira<sup>12</sup> and on behalf of the MAGNIMS study group



2

N. De Stefano

# INNI – Sclerosi Multipla

JOURNAL OF MAGNETIC RESONANCE IMAGING 37:1-14 (2013)

Review

## Clinical Use of Brain Volumetry

CME

Antonio Giorgio, MD, PhD and Nicola De Stefano, MD, PhD\*



### Use of MRI-based brain volumetry in different clinical scenarios

Supporting disease diagnosis	Understanding mechanisms and tracking clinical progression of disease	Monitoring treatment effect
Alzheimer's disease	Alzheimer's disease	Alzheimer's disease
Frontotemporal dementia	Multiple sclerosis	Multiple sclerosis
Focal epilepsy	Focal epilepsy	
Parkinsonisms	Headache/migraine	
	Amyotrophic lateral sclerosis	
	CADASIL	

N. De Stefano

Gemelli



apr. '23





BEST HOSPITALS  
L'OSPEDALE IN ITALIA  
POLICLINICO UNIVERSITARIO A. GEMELLI  
2022  
Newsweek  
statista


# INNI – Sclerosi Multipla

## MRI-Based measures to assess brain volumes


- Linear measurement of the third ventricle and lateral ventricles<sup>2</sup>



- BPF: distinguishes skull and CSF from brain tissue<sup>3</sup>




**BPF = 0.7937**



**BPF = 0.7746,**  
(difference: -0.0191, % change: -2.40)

- SIENA: registration based approach



1. Cohen RM, et al. Neurobiol Aging 2006;27(10):1385-94; 2. Simon JH, et al. Neurology 1999;53(1):139-48;  
3. Fisher E, et al. . Neurology 2002;59(9):1412-20; 4. Battaglini M, et al. . J Neurol Sci 2009;282(1-2):55-60

4

N. De Stefano

# Challenges to the Use of BV in Clinical Practice

Category	Topic
Physiological factors [11, 57, 64, 66, 70, 74, 75]	Age Body mass index Diurnal variation Genotype (ApoE expression) Hydration state Menstrual cycle
Disease-related factors [11, 57, 64, 74–77]	Fluid-level changes attributable to inflammation (edema) Fluid-level changes attributable to resolution of inflammation (treatment-related pseudoatrophy)
Habits and comorbidities [11, 64, 66, 74]	Alcohol consumption Cardiovascular hypertension Diabetes mellitus Obesity Smoking
MRI-related factors [11, 57, 64, 65, 74, 76]	Changes in acquisition protocols Changes in scanner type and scanner upgrades Factors influencing scan quality (head motion, distortions, inhomogeneity artifacts) Measurement error Non-standardized quantification methods Patient repositioning in the scanner Reimbursement
Logistical factors [11, 57, 64, 65, 76]	Complexity of use (e.g. PACS integration) Lack of normative data Methods dependent on real-time data Poor integration of some image formats

# INNI – Sclerosi Multipla

## Challenges to the Use of BV in Clinical Practice

- ❖ MRI Acquisition
- ❖ MRI Analysis
- ❖ Data interpretation

De Stefano et al CNS Drugs 2017

6

N. De Stefano



# INNI – Sclerosi Multipla

## MRI Acquisition for Volumetry - GE

GE 1.5T Signa Excite, Discovery, Optima, Brivo, Voyager, Creator, Explorer & Artist Excite, Discovery, Pioneer, Architect and Premier					GE 3T Signa
	Sequence name	1.5 T	1.5 T	3 T	3 T
Imaging parameters	Plane	Sagittal	Sagittal	Sagittal	Sagittal
	Mode	3D	3D	3D	3D
	Pulse sequence	FSPGR	FSPGR	FSPGR	FSPGR
	Grad Mode (twinspeed only)	Zoom	Zoom	Zoom	Zoom
	Imaging options	EDR, Fast, IR prep, Asset/ARC			
Acquisition	Freq. FOV	25.0	25.0	25.0	25.0
	Phase FOV	1.0	1.0	1.0	1.0
	Slice thickness	1.0	1.0	1.0	1.0
	Spacing (2D)				
	Freq Dir	SI	SI	SI	SI
	TR (ms)	-	-	-	-
	# slices / locs per slab	192	192	192	192
Details	Chem SAT				
	# of TE(s) per scan	1	1	1	1
	Num shots				
	TE (ms)	Min Full	Min Full	Min Full	Min Full
	Flip angle	12	12	11	11
	Prep Time/T1 (ms)	400	400	450	450
	ETL				
	Intensity Correction	PURE	PURE	PURE	PURE
	Intensity Filter	None	None	None	None
	3D Geometry Corr	Yes	Yes	Yes	Yes
Acceleration	Frequency	256	256	256	256
	Phase	256	256	256	256
	NEX	1	1	1	1
	Bandwidth (kHz)	22.5	22.5	22.73	22.73
	Flow comp direction	-	-	-	-
Additional instructions	Phase	1,75/2	1,75/2	1,75/2	1,75/2
	Slice	1/1,5	1/1,5	1/1,5	1/1,5
User CV	Excitation = Slab Selective	Excitation = NON Selective	Excitation = Slab Selective	Excitation = Slab Selective	Excitation = NON Selective
Other	No ZIP2. No ZIP512. Use of HyperSense is allowed if available.	No ZIP2. No ZIP512. Use of HyperSense is allowed if available.	No ZIP2. No ZIP512. Use of HyperSense is allowed if available.	No ZIP2. No ZIP512. Use of HyperSense is allowed if available.	No ZIP2. No ZIP512. Use of HyperSense is allowed if available.
Scan info	Imaging time	~4:40	~4:40	~4:40	~4:40

7

N. De Stefano



apr. '23



72

# INNI – Sclerosi Multipla

## MRI Acquisition for Volumetry - Siemens

Siemens 1.5T SymphonyTim, Espreo, Essenza, Avanto, Amira, Aera, Sempra and Sola Verio, Skyra, Spectra, Prisma, Biograph mMR, Vida and Lumina					Siemens 3T Trio,
	1.5 T	1.5 T	3 T	3 T	
Sequence name	Spine 3D MP-RAGE	Brain 3D MP-RAGE	Spine 3D MP-RAGE	Brain 3D MP-RAGE	
Sequence variant	*tf3d1_ns	*tf3d1_ns	*tf3d1_ns	*tf3d1_ns	
Orientation	Sagittal	Sagittal	Sagittal	Sagittal	
Phase enc. direction	A >> P	A >> P	A >> P	A >> P	
Phase oversampling [%]	0 - 16,7	0 - 16,7	0 - 16,7	0 - 16,7	
Slice oversampling [%]	12.5	16.7	12.5	16.7	
Slices per group/slab	192	192	192	192	
FOV read [mm]	250	250	250	250	
FOV phase [%]	100	100	100	100	
Slice thickness [mm]	1.0	1.0	1.0	1.0	
Distance factor [%]					
TR [ms]	2200/2300	2200/2300	2300/2400	2300/2400	
TE [ms]	minimum	minimum	minimum	minimum	
Averages	1	1	1	1	
Concatenations					
Measurements	1	1	1	1	
Magn. preparation	Sel IR.	Non-Sel IR.	Sel IR.	Non-Sel IR.	
T1 [ms]	900/950	900/950	900/1050	900/1050	
Flip Angle	8	8	9	9	
Fat suppr.	None	None	None	None	
Base resolution	256	256	256	256	
Phase resolution [%]	100	100	100	100	
Slice resolution [%]	100	100	100	100	
Phase partial Fourier	Off	Off	Off	Off	
Slice partial Fourier	Off	Off	Off	Off	
Resolution					
Filter	Prescan Normalize. Elliptical Filter Distortion Corr. 3D	Prescan Normalize. Elliptical Filter Distortion Corr. 3D	Prescan Normalize. Elliptical Filter Distortion Corr. 3D	Prescan Normalize. Elliptical Filter Distortion Corr. 3D	
Interpolation	Off	Off	Off	Off	
iPAT	Grappa/CAIPIRINA acceleration AP = 2, Acceleration RL= 1	Grappa/CAIPIRINA acceleration AP = 2, Acceleration RL= 1	Grappa/CAIPIRINA acceleration AP = 2, Acceleration RL= 1 - 2	Grappa/CAIPIRINA acceleration AP = 2, Acceleration RL= 1 - 2	
Sequence					
Contrasts					
Bandwidth [Hz/Px]	130	130	190	190	
Flow comp.	No	No	No	No	
Asymmetric echo	Allowed	Allowed	Allowed	Allowed	
Turbo factor					
Gradient mode	Fast	Fast	Fast	Fast	
Excitation	Non-sel.	Non-sel.	Non-sel.	Non-sel.	
RF spoiling	On	On	On	On	
Additional instructions	USE of GRASP is allowed if available	USE of GRASP is allowed if available	USE of GRASP is allowed if available	USE of GRASP is allowed if available	
Approximate scan time [min:sec]	-5:00	-5:00	-5:00	-5:00	

8

N. De Stefano



apr. '23



73

# INNI – Sclerosi Multipla

## MRI Acquisition for Volumetry - Philips

PROTOCOL FOR sagittal 3D T1-W OF THE BRAIN AND C-SPINE Philips 1.5 T & 3 T (Intera, Achieva, and Ingenia)				
	1.5 T	1.5 T	3 T	3 T
Sequence name	Spine 3D BrainVIEW T1	Brain 3D BrainVIEW T1	Spine 3D BrainVIEW T1	Brain 3D T1
CLEAR	yes	yes	yes	yes
FOV (mm)	250 (AP) × 250 (FH) × 192 (RL)	250 (AP) × 250 (FH) × 192 (RL)	250 (AP) × 250 (FH) × 192 (RL)	250 (AP) × 250 (FH) × 192 (RL)
RFOV (%)	100	100	100	100
Foldover suppression	no	no	no	no
Voxel size (mm)	0.98 (AP) × 0.98 (FH) × 1.0 (RL)	0.98 (AP) × 0.98 (FH) × 1.0 (RL)	0.98 (AP) × 0.98 (FH) × 1.0 (RL)	0.98 (AP) × 0.98 (FH) × 1.0 (RL)
Recon voxel size (mm)	0.98 (AP) × 0.98 (FH) × 1.0 (RL)	0.98 (AP) × 0.98 (FH) × 1.0 (RL)	0.98 (AP) × 0.98 (FH) × 1.0 (RL)	0.98 (AP) × 0.98 (FH) × 1.0 (RL)
Matrix scan	256	256	256	256
Reconstruction matrix	256	256	256	256
Scan percentage (%)	100	100	100	100
Geometry	S reduction (RL) = 2, P reduction (AP) = 1, P. os factor = 1	S reduction (RL) = 2, P reduction (AP) = 1, P. os factor = 1	S reduction (RL) = 2, P reduction (AP) = 1, P. os factor = 1	S reduction (RL) = 2, P reduction (AP) = 3, P. os factor = 1
	192	192	192	192
	1.0	1.0	1.0	1.0
	overcontiguous = no	overcontiguous = no	overcontiguous = no	overcontiguous = no
	sagittal	sagittal	sagittal	sagittal
	AP	AP	AP	AP
	F	F	F	F
	0	0	0	0
	3D	3D	3D	3D
	FFE	FFE	FFE	FFE
Contrast	T1	T1	T1	T1
	TFE	TFE	TFE	TFE
	multishot	multishot	multishot	multishot
	254	254	254	254
	shortest	shortest	shortest	shortest
	linear	linear	linear	linear
	1	1	1	1
	no	no	no	no
	shortest	shortest	shortest	shortest
	8	8	8	8
Motion	shortest	shortest	shortest	shortest
	no	no	no	no
	0.8/1.6 (user-defined)	0.8/1.6 (user-defined)	1.8/2 (user-defined)	1.8/2 (user-defined)
	invert	invert	invert	invert
	no	no	no	no
	950 (TFE prepulse delay)	950 (TFE prepulse delay)	1060 (TFE prepulse delay)	1060 (TFE prepulse delay)
	no	no	no	no
	no	no	no	no
	1	1	1	1
	USE of CompressedSENSE is allowed if available			
Other	-5:00	-5:00	-5:00	-5:00
Approximate scan time				

9

N. De Stefano



apr. '23

022  
week

statistic

74


# INNI – Sclerosi Multipla

## Brain MRI acquisition protocol

3DT1 Sagittal View



**Slice Thickness:** 1mm  
**N. Slices:** variable,  
depending on neck  
length




# INNI – Sclerosi Multipla

## Image Acquisition – Data Quality

Patient/Operator



Partial head acquisition



Courtesy of Department of Medicine, Surgery and NeuroScience,  
University of Siena, Italy.

11

N. De Stefano




# INNI – Sclerosi Multipla

## Image Acquisition – Data Quality

Patient/Operator



Intensity and movement artifacts



Courtesy of Department of Medicine, Surgery and NeuroScience,  
University of Siena, Italy.


12

N. De Stefano

# INNI – Sclerosi Multipla


## Image Acquisition – Data Quality

- Incorrect repositioning



Baseline

Courtesy of Paola Valsalsina  
& Mara Rocca



Follow-up



N. De Stefano



# INNI – Sclerosi Multipla

Estimating and accounting for the effect of MRI scanner changes on longitudinal whole-brain volume change measurements





Hyunwoo Lee <sup>a,\*</sup>, Kunio Nakamura <sup>b</sup>, Sridar Narayanan <sup>a</sup>, Robert A. Brown <sup>a</sup>, Douglas L. Arnold <sup>a</sup>,  
for the Alzheimer's Disease Neuroimaging Initiative<sup>1</sup>

<sup>a</sup> Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada

<sup>b</sup> Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

NeuroImage 184 (2019) 555–565



N. De Stefano

# INNI – Sclerosi Multipla

Estimating and accounting for the effect of MRI scanner changes on longitudinal whole-brain volume change measurements




Hyunwoo Lee <sup>a,\*</sup>, Kunio Nakamura <sup>b</sup>, Sridar Narayanan <sup>a</sup>, Robert A. Brown <sup>a</sup>, Douglas L. Arnold <sup>a</sup>,  
for the Alzheimer's Disease Neuroimaging Initiative<sup>1</sup>

<sup>a</sup> Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada

<sup>b</sup> Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

NeuroImage 184 (2019) 555–565




15

N. De Stefano

# INNI – Sclerosi Multipla

## Image Acquisition – The issue of standardization



Kruggel et al Neuroimage 2010




# INNI – Sclerosi Multipla

## Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging

Loredana Storelli, MSc • Maria A. Rocca, MD • Elisabetta Pugnani, MSc • Wim Van Hecke, PhD • Mark A. Horsfield, PhD • Nicola De Stefano, MD, PhD • Alex Rovira, MD • Jaume Sastre-Garriga, MD • Jacqueline Palace, MD • Diana Sima, PhD • Dirk Smeets, PhD • Massimo Filippi, MD • for the MAGNIMS Study Group

- 19 MS (Philips 1.5T & 3T)



a.


- Great repeatability (within system), but poor reproducibility (among different systems/field strengths)
- An improved reproducibility is required for clinical application

17

N. De Stefano

# INNI – Sclerosi Multipla

## Brain Volume Change: A Composite of Multiple Pathophysiological Mechanisms




N. De Stefano



# INNI – Sclerosi Multipla

## Interpreting Brain Atrophy in MS Pseudoatrophy



Giorgio A, et al. J Magn Reson Imaging 2013;37(1):1-14

N. De Stefano



# INNI – Sclerosi Multipla



RESEARCH ARTICLE

Annals of Clinical and Translational  
Neurology 2021; 8(8): 623-630

## Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalization


Nicola De Stefano<sup>1</sup>, Antonio Giorgio<sup>1</sup>, Giordano Gentile<sup>1</sup>, Maria Laura Stromillo<sup>1</sup>, Rosa Cortese<sup>1</sup>, Claudio Gasperini<sup>2</sup>, Andrea Visconti<sup>3</sup>, Maria Pia Sormani<sup>4</sup> & Marco Battaglini<sup>1</sup>

<sup>1</sup>Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy

<sup>2</sup>San Camillo-Forlanini Hospital, Rome, Italy

<sup>3</sup>Medical Affairs Department, Merck Serono, Rome, Italy

<sup>4</sup>Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy



20

N. De Stefano



apr. '23




85

# INNI – Sclerosi Multipla

## Standardised brain MRI protocol for MS monitoring

Initial	New baseline	First follow-up*†	Second follow-up*†	Follow-ups*†
Pretreatment‡	3–6 months after treatment onset§	12 months after treatment onset	24 months after treatment onset	Every year while on treatment¶
Gadolinium recommended	Gadolinium usually not required	Gadolinium optional	Gadolinium optional	Gadolinium optional



**Magnetic field strength:** 3T (recommended, not mandatory)

**Spatial resolution:**

2D: 3 mm slice thickness (no gap), in-plane 1x1 mm

3D: isotropic voxel size 1x1x1 mm

Wattjes MP...Rovira A. *Lancet Neurol* 2021;20:653-670  
 Rovira A et al. *Nat Rev Neurol* 2015;11:471-82  
 Wattjes MP et al. *Nat Rev Neurol* 2015; 11: 597-606



N. De Stefano




# INNI – Sclerosi Multipla

Can we assess brain atrophy in the single patient?

- ❖ Increasing desire to use measures of brain volumes in clinical setting.
  - ❖ To assess prognosis
  - ❖ To monitor treatment effect

## Integrated Platforms for MRI Quantification

- ✓ BrainMagix - amagylis
- ✓ Icobrain MS – icometrix
- ✓ Lesion Quant – Neuroquant
- ✓ Quantib ND - quantib
- ✓ Olea – subtraction module
- ✓ SIENA Imaging - SinLab



**SCLE  
ROSI  
MULTIPLA**  
fondazione  
Ricerca

un mondo  
libero della SM



N. De Stefano



## Conclusions

- ◆ MRI-derived measures of brain volumes are feasible, sensitive to changes and clinically relevant. Need of **standardised MRI acquisition**
- ◆ Issues with **data processing**. To be done in specialized centres
- ◆ Issue with **data interpretation** (e.g. confounding factors). To be done by the clinician.
- ◆ Increasing desire to use measures of brain volumes in the clinical setting. **Difficult for single patient assessment.**



N. De Stefano



# INNI – Sclerosi Multipla

**21 Giugno 2022 - Corso Virtuale**

"The Italian neuroimaging network initiative (INNI): verso la standardizzazione dell'utilizzo della RM nel paziente con sclerosi multipla a livello nazionale"



## Collaborazione con il Registro SM: condivisione della survey conoscitiva

*Antonio Gallo*

Centro SM – 3TMRI Research Center

Dipartimento "DAMSS"

Università della Campania "Luigi Vanvitelli"



A. Gallo

# INNI – Sclerosi Multipla

## REGISTRO ITALIANO SCLEROSI MULTIPLA

**Esordio**

Data esordio SM: 01/06/1996

Nota: è obbligatorio inserire Data esordio SM oppure selezionare RIS=Si in caso di Sindrome Radiologicamente Isolata.

RIS: Si No ↗ Data RIS: gg/mm/aaaa

Sintomi troncoencefalici: Si No ↗ Sintomi vie ottiche: Si No ↗ Sintomi midollo spinale: Si No ↗ Sintomi soprattoriali: Si No ↗

Altri sintomi: Si No ↗

Specificare:

Progressione all'esordio: Si No ↗ Data inizio progressione: 15/06/2007

**Diagnosi**

Data diagnosi: 05/03/1997

Criterio conferma diagnosi: Diagnosi SM → Criterio conferma diagnosi: Diagnosi SM

Diagnosi SM: Selezione, Diagnosi SM, NMO, NMO Spectrum, No SM, Possible SM, SM secondo McDonald 2001, SM secondo McDonald 2010, SM secondo McDonald 2017

Data prima visita nel centro: 10/02/1999

Note:

### Esordio e Diagnosi

A. Gallo



apr. '23



# INNI – Sclerosi Multipla

## REGISTRO ITALIANO SCLEROSI MULTIPLA

data esame  
gg/mmn/aaaa

Risonanza Magnetica

Tipo di Magnete Utilizzato	Area SNC esaminata	Somministrazione di Gadolinio
Selezione	Selezione...	<input type="checkbox"/> Sì <input type="checkbox"/> No <input type="checkbox"/> Non so

Informazioni minime obbligatorie - Criteri Mc Donald 2017 DIS

Presenza di Lesioni in T1	<input type="checkbox"/> Sì <input type="checkbox"/> No <input type="checkbox"/>
Presenza di Lesioni in T1 captanti Gadolinio	<input type="checkbox"/> Sì <input type="checkbox"/> No <input type="checkbox"/>
Presenza di nuove lesioni o di lesioni aumentate di volume in T2 rispetto a RMN precedente	<input type="checkbox"/> Sì <input type="checkbox"/> No <input type="checkbox"/>
Numero totale di lesioni in T2	Selezione
Selezionare Area SNC per vedere le opzioni	
Soddisfatti i Criteri di Mc Donald 2017 per la disseminazione temporale	
<input type="checkbox"/> Sì <input type="checkbox"/> No <input type="checkbox"/>	

Informazioni aggiuntive - Criteri Mc Donald 2017 DIS  
(in riferimento alle lesioni del SNC esaudito e midollo spinale)

Iperintense in T2 sede corticale/extra-corticale	Iperintense in T2 sede periventricolare	Iperintense in T2 sede infratentoriale	Iperintense in T2 a carico del midollo spinale
Selezione	Selezione...	Selezione...	Selezione...

Soddisfatti i Criteri di Mc Donald 2017 per la disseminazione spaziale

Mostra informazioni  Calcola automaticamente

Sì  No

Allegati

Nessun allegato presente

Carica nuovi allegati

Scegli file: Nessun file selezionato

Note

### Inserimento RMN Basale e al Follow-up

A. Gallo



apr. '23



# INNI – Sclerosi Multipla

## INTEGRAZIONE RISM-RM

- Obiettivo strategico di FISM e del RISM:

**Integrazione dei dati clinico-demografici-terapeutici del RISM con gli esami RM dei pazienti, al fine di poter svolgere studi retrospettivi e prospettici (di correlazione, monitoraggio e predizione) ancora più accurati e completi.**

Questo avanzamento del RISM prevede che i Centri SM possano caricare sulla piattaforma/server del RISM (sempre in maniera criptata) gli esami di RM dei pazienti, laddove vengano richiesti per un progetto del RISM (\*) che prevede l'analisi anche dei dati di RM.

**Survey conoscitiva** sviluppata dai *core centers* di INNI (durata per la compilazione ca. 15 minuti)(\*\*) per "fotografare" le attuali procedure di acquisizione/gestione degli esami RM eseguiti presso i Centri SM partecipanti al RISM.

(\*) possibile/da valutare anche, per i Centri SM che lo preferissero, un caricamento dei dati continuo/parallelo all'inserimento dei dati clinici

(\*\*) valutare anche il supporto e la condivisione con un neuroradiologo della struttura a cui afferisce il Centro SM

A. Gallo

## Survey RISM-RM (6)

### STUDIO ENCEFALO

Linee guida MAGNIMS-CMSC-NAIMS 2021 (requisiti minimi) - Wattjes et al. Lancet Neurology 2021

#### Raccomandate:

- Immagini T2 (TSE o FSE) assiali con spessore  $\leq 3$  mm, gap 0 mm e risoluzione sul piano  $1 \times 1 \times 1$  mm
- Immagini T2-FLAIR sagittali (meglio se 3D T2-FLAIR isotropiche  $1 \times 1 \times 1$  mm o cmq con spessore sempre  $\leq 1.5$  mm)
- Immagini T2-FLAIR assiali (**se non disponibile immagini 3D T2-FLAIR sagittali**) con spessore  $\leq 3$  mm, gap 0 mm
- Immagini T1 assiali post-mdc (oppure 3D sagittali) (raccomandate alla diagnosi; opzionali durante il monitoraggio)

#### Opzionali:

- Immagini 3D-T1 isotropiche ad alta risoluzione, DWI, DIR, PSIR, SWI

# INNI – Sclerosi Multipla

## Survey RISM-RM (8)

Quanti esami RM del midollo cervicale di pazienti con SM vengono eseguiti in media ogni anno con questo scanner e con il suddetto protocollo standardizzato? *menù a scelta multipla: <50/anno, 50-100/anno, >100/anno, >200/anno, >500/anno*

Quanti esami RM del midollo cervicale di pazienti con SM sono stati eseguiti fino ad oggi con questo scanner e con il suddetto protocollo standardizzato? *menù a scelta multipla: <50, 50-100, >100, >200, >500*

Quanti degli esami RM del midollo cervicale eseguiti fino ad oggi, con questo scanner e con il suddetto protocollo standardizzato, rispettano i requisiti minimi previsti specificamente dalle recenti linee guida MAGNIMS-CMSC-NAIMS 2021 (riportate di seguito)? *menù a scelta multipla: <50, 50-100, >100, >200, >500, Non so, Altro/Commenti (specificare)*

---

**Linee guida MAGNIMS-CMSC-NAIMS 2021 (requisiti minimi) - Wattjes et al. Lancet Neurology 2021**

**Raccomandate:**

- Almeno 2 immagini/sequenze sagittali tra le seguenti: T2 (TSE o FSE), PD (TSE o FSE) o STIR con spessore ≤3 mm, gap 0 mm
- Immagini T1 sagittali dopo contrasto (raccomandate alla diagnosi; opzionali durante il monitoraggio)

**Opzionali:**

- Immagini T1 sagittali e assiali pre-contrastio, T2 assiali (TSE o FSE), 3D-T1 sagittali (PSIR, FSPGR, MPRAGE)
- 

A. Gallo

